Dermapharm ex-dividend date approaches, shares in the SDAX healthcare segment
25.06.2026 - 17:44:51 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 17:44.
Dermapharm Holding SE (DE000A2GS5D8) enters the coming days with a clear dividend focus on Xetra. According to recent analysis, the shares are expected to trade ex-dividend shortly, which typically draws attention from income-oriented investors in the SDAX healthcare space. Recent Simply Wall St dividend commentary
What recent reports highlight
A recent dividend-focused note points out that Dermapharm Holding SE is set to go ex-dividend in the near term on the Frankfurt-based Xetra market, meaning new buyers after that date will not receive the next payout. Dividend-focused analysis on Dermapharm The commentary underlines that ex-dividend dates generally fall two business days before the record date.
In its previous dividend cycle, Dermapharm paid a distribution tied to its prior-year earnings, which positioned the stock among income-generating healthcare names alongside peers such as Bayer and Zealande Pharma in European portfolios. Finanzen.net profile on Dermapharm The upcoming ex-dividend timing therefore serves as a concrete calendar marker for investors following payout strategies.
Consensus and analyst perspective
Analyst coverage compiled on platforms such as MarketScreener and finanzen.net shows that Dermapharm is typically rated in the Buy to Hold range, with a number of research houses emphasizing its stable cash generation and recurring revenues from branded generics and portfolio products. MarketScreener consensus overview While individual price targets vary, the consensus framework helps investors gauge expected total return when combining dividends and potential capital appreciation.
Dermapharm, listed in the SDAX and trading on Xetra under the ticker DMP, is regularly compared with other mid-cap European specialty pharma groups in analyst notes, particularly around profitability metrics and balance-sheet flexibility. Boerse Frankfurt listing information This context matters for investors who weigh dividend sustainability against ongoing investment in product development and acquisitions.
All news and analysis on the Dermapharm shares
Further background on Dermapharm, from dividend dates to strategy updates and price data, is available in the dedicated topic overview and on the company's Investor Relations pages.
How Dermapharm makes its money
Dermapharm generates revenue primarily through the development, production and marketing of off-patent branded pharmaceuticals, herbal medicines and healthcare products, including lines like the Dekristol vitamin D range in Germany. The company also derives income from contract manufacturing and selected cosmetic and nutraceutical offerings.
Where the stock trades today
The Dermapharm shares (DE000A2GS5D8) most recently traded on Xetra at around the mid-40-euro range, with the latest available price on 2026-06-25, 17:30, showing approximately 44.50 euros per share.
Key data on the Dermapharm shares
- Company: Dermapharm Holding SE
- ISIN: DE000A2GS5D8
- WKN: A2GS5D
- Ticker: DMP
- Trading venue: Xetra
- Price (as of 2026-06-25, 17:30): 44.50 EUR
- Market cap: approximately 2.4 billion EUR (as of 2026-06-25)
- Sector / industry: Pharmaceuticals / Specialty Pharma
- Index membership: SDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data are based on sources believed to be reliable but cannot be guaranteed.
